Applied DNA Sciences Inc (APDN), through its subsidiary Applied DNA Clinical Labs (ADCL), has taken a significant step in the fight against mpox by expanding its clinical testing services. This move has resulted in a remarkable 37% surge in the company’s stock price, pushing it up to $1.76 on Wednesday morning.
The expanded services now encompass the detection of both Mpox Clade I and Clade II, a critical development approved by regulatory bodies like the New York State Department of Health and the FDA. Applied DNA Sciences emphasizes that this expansion is designed to support New York and other states in their efforts to combat the escalating mpox threat by increasing access to testing.
ADCL’s Linea Mpox Virus 1.0 Assay, initially approved in 2022 for detecting Clade II, has recently undergone validation to also detect Clade I. This testing will be conducted at ADCL’s laboratory in Stony Brook, New York.
For investors looking to gain exposure to Applied DNA Sciences, options beyond direct stock purchase include ETFs (exchange traded funds) that hold the company’s stock or strategies within 401(k) plans that target investments in the healthcare sector, where APDN falls. ETFs are particularly valuable as they provide access to a range of liquid and large companies within a specific sector, offering exposure to sector-specific trends.
APDN has experienced significant fluctuations in its stock price over the past year, with a 52-week high of $28.40 and a 52-week low of $0.31.
